Conjugate vaccine

For bacteria with a polysaccharide coating, like Haemophilus influenzae type b, the best way to prevent infection is to use a conjugate vaccine.[1]

A conjugate vaccine is a type of subunit vaccine which combines a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.

Vaccines are used to prevent diseases by invoking an immune response to an antigen, part of a bacterium or virus that the immune system recognizes.[2] This is usually accomplished with an attenuated or dead version of a pathogenic bacterium or virus in the vaccine, so that the immune system can recognize the antigen later in life.[2]

Most vaccines contain a single antigen that the body will recognize. However, the antigen of some pathogens does not elicit a strong response from the immune system, so a vaccination against this weak antigen would not protect the person later in life. In this case, a conjugate vaccine is used in order to invoke an immune system response against the weak antigen. In a conjugate vaccine, the weak antigen is covalently attached to a strong antigen, thereby eliciting a stronger immunological response to the weak antigen. Most commonly, the weak antigen is a polysaccharide that is attached to strong protein antigen. However, peptide/protein and protein/protein conjugates have also been developed.[3]

History

The idea of a conjugate vaccine first appeared in experiments involving rabbits in 1927, when the immune response to the Streptococcus pneumoniae type 3 polysaccharide antigen was increased by combining the polysaccharide antigen with a protein carrier.[4][5] The first conjugate vaccine used in humans became available in 1987.[5] This was the Haemophilus influenzae type b (Hib) conjugate, which protects against meningitis. The vaccine was soon incorporated with the schedule for infant immunization in the United States.[5] The Hib conjugate vaccine is combined with one of several different carrier proteins, such as the diphtheria toxoid or the tetanus toxoid.[6] Soon after the vaccine was made available the rates of Hib infection dropped, with a decrease of 90.7% between 1987 and 1991.[6] Infection rates diminished even more once the vaccine was made available for infants.[6]

Technique

Vaccines evoke an immune response to an antigen, and the immune system reacts by producing T cells and antibodies.[2] The B memory cells remember the antigen so that if the body encounters it later, antibodies can be produced by B cells to break down the antigen. For bacteria with a polysaccharide coating, the immune response creates B cells independent of T cell stimulation.[7] By conjugating the polysaccharide to a protein carrier, a T cell response can be induced. Normally, polysaccharides by themselves cannot be loaded onto the major histocompatibility complex (MHC) of antigen presenting cells (APC) because MHC can only bind peptides. In the case of a conjugate vaccine, the carrier peptide linked to the polysaccharide target antigen is able to be presented on the MHC molecule and the T cell can be activated. This improves the vaccine as T cells stimulate a more vigorous immune response and also promote a more rapid and long-lasting immunologic memory. The conjugation of polysaccharide target antigen to the carrier protein also increases efficiency of the vaccine, as a non conjugated vaccine against the polysaccharide antigen is not effective in young children.[6] The immune systems of young children are not able to recognize the antigen as the polysaccharide covering disguises the antigen.[2] By combining the bacterial polysaccharide with another antigen, the immune system is able to respond.[citation needed]

Approved conjugate vaccines

A vial of Soberana 02 vaccine in Iran for use in the phase III clinical trials

The most commonly used conjugate vaccine is the Hib conjugate vaccine. Other pathogens that are combined in a conjugate vaccine to increase an immune response are Streptococcus pneumoniae (see pneumococcal conjugate vaccine) and Neisseria meningitidis (see meningococcal vaccine), both of which are conjugated to protein carriers like those used in the Hib conjugate vaccine.[6] Both Streptococcus pneumoniae and Neisseria meningitidis are similar to Hib in that infection can lead to meningitis.[6]

In 2018, World Health Organization recommended the use of the typhoid conjugate vaccine[8] which may be more effective and prevents typhoid fever in many children under the age of five years.[9]

In 2021, Soberana 02, a conjugate COVID-19 vaccine developed in Cuba, was given emergency use authorisation in Cuba and Iran.[10][11]

Select list of other conjugate vaccines

See also: Substance use disorder § Potential vaccines for addiction to substances

See also

References

  1. ^ "Immunization: You Call the Shots". www2.cdc.gov. Archived from the original on 2010-06-03. Retrieved 2018-11-29.
  2. ^ a b c d "Understanding How Vaccines Work | CDC". www.cdc.gov. 2018-10-18. Archived from the original on 2020-01-02. Retrieved 2018-11-29.
  3. ^ Rappuoli, Rino.; Bagnoli, Fabio., eds. (2011). Vaccine design : innovative approaches and novel strategies. Norfolk, UK: Caister Academic. ISBN 9781904455745. OCLC 630453151.
  4. ^ Avery, Ostwald (1929). "Chemo-immunological studies on conjugated carbohydrate-proteins: II. Immunological specificity of synthetic sugar-protein antigens". Journal of Experimental Medicine. 50 (4): 533–550. doi:10.1084/jem.50.4.533. PMC 2131643. PMID 19869645.
  5. ^ a b c Goldblatt, D. (January 2000). "Conjugate vaccines". Clinical and Experimental Immunology. 119 (1): 1–3. doi:10.1046/j.1365-2249.2000.01109.x. ISSN 0009-9104. PMC 1905528. PMID 10671089.
  6. ^ a b c d e f Ahmad, Hussain; Chapnick, Edward K. (March 1999). "Conjugated Polysaccharide Vaccines". Infectious Disease Clinics of North America. 13 (1): 113–33. doi:10.1016/s0891-5520(05)70046-5. ISSN 0891-5520. PMID 10198795.
  7. ^ Lee C, Lee LH, Koizumi K (2002). "Polysaccharide Vaccines for Prevention of Encapsulated Bacterial Infections: Part 1". Infect. Med. 19: 127–33.
  8. ^ World Health Organization (4 April 2018). "Typhoid vaccines: WHO position paper – March 2018" (PDF). Weekly Epidemiological Record. 93 (13): 153–72. hdl:10665/272273. Archived (PDF) from the original on 10 April 2020. Retrieved 3 December 2019.
  9. ^ Lin, FY; Ho, VA; Khiem, HB; Trach, DD; Bay, PV; Thanh, TC; Kossaczka, Z; Bryla, DA; Shiloach, J; Robbins, JB; Schneerson, R; Szu, SC (26 April 2001). "The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children". The New England Journal of Medicine. 344 (17): 1263–69. doi:10.1056/nejm200104263441701. PMID 11320385.
  10. ^ "Cuba grants emergency approval to second homegrown COVID-19 vaccine". GMA News. 21 August 2021. Archived from the original on 29 November 2022. Retrieved 4 October 2021.
  11. ^ "Autorizo de emergencia SOBERANA 02 en Irán". finlay.edu.cu. Instituto Finlay de Vacunas. 1 July 2021. Archived from the original on 12 July 2021. Retrieved 6 July 2021.